CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
NCT06962904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2026-03-05
Summary
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Conditions
- Rotavirus Infections
Interventions
- BIOLOGICAL
-
3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
- BIOLOGICAL
-
7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
- OTHER
-
Placebo
Placebo MNP (containing sucrose, sorbitol, maltodextrin, methylcellulose, HEPES, sodium chloride, and calcium chloride) administered intradermally
Sponsors & Collaborators
-
Emory-Children's Center
collaborator OTHER -
Children's Hospital Medical Center, Cincinnati
collaborator OTHER -
Micron Biomedical, Inc
collaborator INDUSTRY -
Centers for Disease Control and Prevention
lead FED
Principal Investigators
-
Christina Rostad, MD · Emory Children's Center - Vaccine Research Clinic (ECC-VRC)
-
Lauren Nolan, PA-C · Emory Children's Center - Vaccine Research Clinic (ECC-VRC)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-07-07
- Primary Completion
- 2026-10-06
- Completion
- 2026-10-06
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults
NCT02669121 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)
NCT00953056 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants
NCT02133690 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Clinical Trial of the Inactivated Rotavirus Vaccine
NCT06080906 ·Status: RECRUITING ·Phase: PHASE2
-
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
NCT03537508 ·Status: COMPLETED ·Phase: PHASE3
-
Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)
NCT00496054 ·Status: COMPLETED ·Phase: PHASE3
-
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
NCT00130832 ·Status: COMPLETED ·Phase: PHASE3
-
Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine
NCT01738074 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
NCT03897309 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
NCT06350058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants
NCT03507738 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)
NCT02062385 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children
NCT00262028 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
NCT02992197 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
NCT00262041 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Confirmation Efficacy Study (V260-007)
NCT00092443 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT03691610 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
NCT01272180 ·Status: COMPLETED ·Phase: PHASE2
-
PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
NCT06967272 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
NCT03077438 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults
NCT02810340 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
NCT00262002 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA
NCT06896136 ·Status: COMPLETED ·Phase: PHASE1
-
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
NCT01274897 ·Status: COMPLETED ·Phase: PHASE3